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ABSTRACT
Background: Non-alcoholic fatty liver disease (NAFLD) has been recognized as the most 
common cause of chronic liver disease worldwide. It occurs in patients who do not 
consume alcohol in large amounts. Alanine aminotranferase (ALT) and aspartate ami-
notransferase (AST) are indicators of hepatocellular injury.
Objectives: To determine correlation between histopathologic specifications of NAFLD 
in patients with little or no history of alcohol consumption and the serum level of 
ALT. 
Patients and Methods: In a cross-sectional study carried out in two gastroenterology and 
hepatology clinics in Tehran, Iran, the medical records of those who had undergone 
liver biopsies between years 2005 and 2009 were reviewed. Clinical and laboratory 
information of biopsy-proven cases of NAFLD were obtained from 147 eligible medical 
records. The histopathologic, demographic, and laboratory data of the participants 
were also collected. Two groups of patients according to their serum ALT level (cut-
point of 35 U/L) were defined. The quantitative pathologic grade of the biopsy speci-
mens was determined based on Brunt scoring system.
Results: We studied 147 NAFLD patients including 127 men (86.4%) and 20 women (13.6%) 
with a mean ± SD age of 41.4 ± 11.2 years. Considering serum ALT, the mean ± SD quan-
titative grade of hepatosteatosis was 1.50 ± 0.67 and 1.74 ± 0.73 (p=0.136); advanced fi-
brosis (consisted of grade III and cirrhosis) was found in 4.5% (1/22) and 5.6% (7/125) of 
patients (p=0.327). 
Conclusions: We found that using the cut-off value of 35 U/L for serum ALT level, it has 
little contribution to predict NAFLD severity.
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  Implication for health policy/practice/research/medical education: 
Metabolic syndrome and NAFLD is considered as the most common cause of CLD worldwide. Due to its importance, we recommend 
reading it to all internists, infectious disease specialists and nutritionists.
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1. Background 
Non-alcoholic  fatty  liver  disease  (NAFLD)  has  been 
recognized as the most common cause of chronic liver Hepat Mon. 2011;11(6):452-458
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disease worldwide (1-4). By definition, NAFLD occurs in 
patients who do not consume large amount of alcohol. 
NAFLD has a wide histological spectrum ranging from 
macrovesicular steatosis which is usually a benign and 
non-progressive process to non-alcoholic steatohepatitis 
(NASH),  liver  cirrhosis,  portal  hypertension  and 
hepatocellular carcinoma (5-8).
NAFLD is frequently associated with obesity, diabetes 
mellitus  and  the  metabolic  syndrome.  Currently,  it  is 
considered as a part of the metabolic syndrome (9, 10). 
Hepatic  transaminases,  alanine  (ALT)  and  aspartate 
aminotransferase (AST) are indicators of hepatocellular 
injury.  Several  studies  demonstrated  that  high  levels 
of ALT are correlated with a higher risk of NASH (11, 12). 
However, some studies have shown that patients with 
normal  ALT  levels  may  also  have  histological  features 
of NASH and be at risk for disease progression (13, 14). 
Additionally, some recent studies have introduced a new 
ALT upper limit for a healthy individual which is ≤ 40 U/L 
for both genders. Elevated levels of ALT are sometimes 
associated  with  underlying  NAFLD  (15).  On  the  other 
hand, the current evidence on this issue is inconclusive 
and different normal ranges have been proposed. 
2. Objectives
We  conducted  this  study  to  determine  clinical  and 
histopathologic characteristics of patients with NAFLD 
and their possible correlation with serum ALT level.
3. Patients and Methods 
This  cross-sectional  study  was  carried  out  in  two 
gastroenterology and hepatology clinics in Tehran, Iran. 
Considering  all  medical  records,  consecutive  biopsy-
proven  cases  of  NAFLD  were  recruited.  Initially,  the 
medical records of those who had undergone liver biopsy 
between 2005 and 2009 were reviewed and those with the 
following criteria were selected: Confirmed diagnosis of 
NAFLD with clinical criteria and biopsy specimens. Only 
those  liver  biopsy  specimens  were  considered  which 
represented fatty liver disease in case of predominantly 
macrovesicular steatosis or documented steatohepatitis. 
Steatohepatitis was also defined by the minimal criteria 
of  hepatic  steatosis  and  scattered,  mainly  lobular 
inflammation with or without Mallory bodies, cytologic 
ballooning,  and  perisinusoidal  fibrosis.  Another 
inclusion criteria was negative serologic markers of viral 
or  autoimmune  hepatitis  (i.e.,  HBsAg,  HCV  Ab  [ELISA], 
HIV  Ab  [ELISA],  antinuclear  antibodies,  anti-smooth 
muscle antibodies, anti-liver/kidney microsomes type 1 
antibodies and negative alpha-1 antitrypsin). 
NASH  is  most  often  discovered  during  routine 
laboratory testing. Additional tests help to confirm the 
presence of NASH and rule out other types of liver disease. 
Imaging modalities (e.g., CT scan, or magnetic resonance 
imaging) may depict fat accumulation in the liver but 
cannot help in differentiation of NASH from other causes 
of liver disease that have a similar picture. A liver biopsy 
is  required  to  confirm  NASH.  Blood  tests  to  measure 
the  liver  function,  levels  of  substances  produced  or 
metabolized by the liver can also help to diagnose NASH 
and differentiate NASH from alcoholic hepatitis. Levels 
of two liver enzymes (AST and ALT) are elevated in about 
90% of people with NASH. 
Moreover, additional blood tests are useful for ruling 
out other causes of liver disease. These usually include 
tests  for  viral  hepatitis  (hepatitis  A,  B,  or  C),  and  may 
include  tests  for  less  common  causes  of  liver  disease. 
Hemochromatosis  and  Wilson  disease  were  ruled  out 
by measuring serum levels of iron, and copper as well as 
ceruloplasmin, respectively. In addition, since patients 
who  had  drunk  more  than  20  g  of  alcohol  per  week, 
was  more  likely  to  suffer  from  other  liver  disorders 
including  Wilson  disease,  hemochromatosis,  primary 
biliary  cirrhosis,  primary  sclerosing  cholangitis,  and 
biliary  obstruction,  and  those  who  consumed  drugs 
known  to  cause  steatohepatitis  (e.g.,  glucocorticoids, 
synthetic  estrogens,  aspirin,  tamoxifen,  amiodarone, 
calcium-channel  blockers,  and  methotrexate),  and 
patients who had positive history of jejunoileal bypass 
surgery, pregnancy or incomplete medical records were 
all excluded from the study.
The study protocol was approved by Ethical Committee 
of Tehran University of Medical Sciences.
3.1. Clinical and Laboratory Data
Clinical  and  laboratory  information  were  obtained 
from  147  eligible  medical  records.  Also,  demographic 
and baseline data (patients’ age , gender and body mass 
index [BMI]), laboratory information on levels of ALT and 
AST, alkaline phosphatase (Alk-P), total serum cholesterol 
and  triglycerides,  low  density  lipoprotein  (LDL),  high 
density  lipoprotein  (HDL),  fasting  blood  sugar  (FBS), 
partial thromboplastin time (PTT), serum platelet count 
and  serum  level  of  gamma-glutamyl  transpeptidase 
(g-GTP)  were  recorded.  These  laboratory  indices  were 
measured using standard techniques. ALT activity was 
classified into “normal” and “elevated” according to the 
reference laboratory cut-off value of 35 U/L. In an attempt 
to determine the healthy range of ALT in the population 
under study, after excluding participants with positive 
viral markers, regular drug users, and alcohol drinkers, 
the upper normal limit (the 95th percentile) of serum ALT 
was 35 U/L. Thus, 22 patients with NAFLD had normal ALT 
(< 35 U/L), while the remaining 125 patients had elevated 
ALT (> 35 U/L). All the measured baseline, clinical and 
laboratory findings were compared between these two 
groups. 
3.2. Histopathologic Assessment 
All patients suspected to have NAFLD who showed no Hepat Mon. 2011;11(6):452-458
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improvement  in  liver  function  after  several  months 
of  diet  and  exercise  therapy  underwent  liver  biopsy. 
To  document  the  definite  diagnosis  of  NAFLD,  all 
liver  biopsy  specimens  were  re-examined  for  fibrosis, 
steatosis,  hepatocyte  ballooning,  and  lobar  and 
portal  inflammation.  The  grading  and  staging  of  all 
biopsy  specimens  were  done  based  on  the  method 
proposed by Brunt et al. by one expert pathologist (16). 
Categorization  of  histopathologic  findings  by  Brunt’s 
method is presented in Table 1. The extent of steatosis 
was semiquantitatively graded from I to III considering 
percentage of cells with fatty droplets as follows: grade 
I, up to 33% steatosis; grade II, 33% to 66% steatosis; and 
grade III, > 66% of hepatocytes involved. Peri-sinusoidal 
fibrosis was scored from 0 to III based on the space of 
zone 3 region involved. The presence of cirrhosis was also 
noted. Moreover, “advanced fibrosis” was defined as the 
presence of bridging fibrosis (grade III) or cirrhosis. 
All  histopathologic  features  of  the  enrolled  patients 
with NAFLD were also evaluated and compared between 
two groups with normal and elevated ALT. Patients with 
advanced fibrosis were omitted from parts of analysis 
because low level of serum ALT in this group of patients 
could  hypothetically  be  attributed  to  the  absence  of 
enzyme-producing hepatocytes.
3.3. Statistical analysis
Statistical  analyses  were  performed  by  SPSS®  for 
Windows® ver 15 (SPSS Inc., Chicago, IL, USA). To test the 
differences  between  parametric  and  non-parametric 
variables in the two study groups, independent-sample 
Student’s  t  test  and  Mann-Whitney  U  test  were  used. 
Categorical variables were analyzed by x2 test. Kendall 
τ  was  calculated  to  evaluate  the  correlation  between 
continuous level of ALT and the categorical variable of 
hepatosteatosis grade. Moreover, to determine a better 
cut-off  value  for  serum  ALT  to  detect  more  advanced 
histopathologic  features  of  patients  with  NAFLD, 
receiver operating characteristics (ROC) curve analysis 
was  performed.  The  area  under  the  curve  (AUC)  and 
the  diagnostic  values  of  each  cut-off  points  including 
sensitivity and specificity were calculated. A p < 0.05 was 
considered statistically significant; a study power of 80% 
was assumed in analysis. 
4. Results
4.1. Baseline characteristics
Among  147  studied  patients  with,  127  (86.4%)  were 
male  and  20  (13.6%)  were  female;  they  had  a  mean  ± 
SD age of 41.4 ± 11.2 (range: 15–70) years. Other baseline 
characteristics  including  serum  lipid  profile  and  liver 
function test (LFT) of the patients are shown in Table 2. 
As it is shown, the mean ± SD serum ALT, AST and Alk-P 
were 99.21 ± 178.25, 54.89 ± 32.41, and 185.04 ± 184.17 U/L, 
respectively. All patients underwent liver biopsies, the 
results of which are shown in Table 3. The most frequent 
grade  of  hepatosteatosis  was  grade  I  in  66  patients 
(44.9%);  the  prevalence  of  grades  II  and  III  were  39.5% 
Finding Grading
Hepatosteatosis
Grade I
Grade II
Grade III
< 33% of hepatocytes affected
33%–66% of hepatocytes affected
> 66% of hepatocytes affected
Fibrosis
No fibrosis
Grade I
Grade II
Grade III
Cirrhosis
No fibrosis
Zone 3 peri-sinusuidal peri-cellular fibrosis, focally or extensively present
Zone 3 peri-sinusuidal peri-cellular fibrosis, with focal or extensive peri-portal fibrosis
Zone 3 peri-sinusuidal peri-cellular fibrosis and peri-portal fibrosis with extensive or focal bridging fibrosis
Cirrhosis
Hepatocyte ballooning
No ballooning
Grade I
Grade II
Grade III
No ballooning
Sometimes, zone 3
Evident, zone 3
Symptomatic, more dominant in zone 3
Lobar inflammation
No change
Grade I
Grade II
No change
Diffuse neutrophils, monocytes at 1 or 2 points in a 20× microscopic field
PMN with ballooning hepatocytes, chronic inflammation at 2 to 4 points in a 20× microscopic field
Portal inflammation
No change
Grade I
Grade II
Grade III
No change
Mild, some portal areas
Mild to moderate, most portal areas
Moderate to severe, most portal areas
Table 1. Histopathologic grading of different findings in liver biopsies of patients with NASHHepat Mon. 2011;11(6):452-458
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(58/147) and 15.6% (23/147), respectively. In addition, 103 
(69.7%) patients with NAFLD patients did not have any 
evidence of fibrosis; liver cirrhosis was detected in five 
(3.4%) patients.
4.2  Characteristic  and  histopathologic  features  of 
patients with NAFLD regarding elevated ALT (> 35 U/L)
Regarding the cut-off value of 35 U/L for serum ALT level, 
the patients were divided into two groups; 22 patients 
had ALT < 35 U/L and 125 had ALT > 35 U/L. The baseline 
and  clinical  characteristics  of  patients  with  NAFLD 
stratified according to their serum ALT level are listed in 
Table 2. The mean ± SD serum total cholesterol level was 
significantly higher in those with elevated ALT (206.66 ± 
51.10 vs. 176.85 ± 36.97 mg/dL, p = 0.014). The mean ± SD 
serum AST level was also significantly higher in patients 
with elevated ALT level (59.97 ± 31.92 vs. 25.14 ± 14.35 U/L, p 
< 0.001). Except for these two variables, the other baseline 
and laboratory characteristics of the patients were not 
significantly different between the two groups.
Patients’ histopathologic findings are presented in Table 
3. The most common grade of hepatosteatosis was grade 
I observed in 59.1% and 42.4% of patients with normal 
and  elevated  serum  ALT  level,  respectively.  There  was 
no significant difference in the mean ± SD quantitative 
grade of hepatosteatosis between the two groups (1.50 ± 
0.67 vs. 1.74 ± 0.73, p = 0.136). Advanced fibrosis (grade III 
and cirrhosis) was reported in 4.5% (1/22) and 5.6% (7/125) 
of  those  with  normal  and  elevated  ALT,  respectively 
(p  =  0.327).  The  mean  ±  SD  grade  of  fibrosis  was  also 
similar in the two groups (0.32 ± 0.95 vs. 0.52 ± 0.94, p 
= 0.104). Other histopathologic findings were also not 
significantly different except for the mean grade of lobar 
inflammation (p = 0.045) (Table 3).
4.3  Relationship  between  serum  ALT  level  and 
histopathologic features of patients with NAFLD 
Analysis  was  performed  to  evaluate  the  association 
between serum ALT level and histopathologic findings 
in  patients  with  NAFLD.  After  exclusion  of  those  with 
advanced fibrosis (No. = 8), a significant direct correlation 
was  found  between  serum  ALT  level  and  grade  of 
hepatosteatosis (p = 0.012). The mean ± SEM serum ALT 
level was also significantly higher in patients with NAFLD 
with > 33% hepatocytes involvement (126.99 ± 28.25 U/L in 
comparison to the those with mild hepatosteatosis (73.14 
± 5.98 U/L) (p = 0.020). Considering the cases of advanced 
fibrosis in analysis, the AST/ALT ratio was significantly 
higher  in  patients  with  NAFLD  who  suffered  from 
advanced fibrosis (mean ± SD: 1.18 ± 0.46 vs. 0.75 ± 0.47, 
p = 0.012). 
4.4  Receiver  Operating  Characteristics  (ROC)  curve 
analysis 
To find a better cut-off value for serum ALT level to predict 
the histopathologic features of patients with NAFLD, ROC 
curve  analysis  was  performed;  it  revealed  that  serum 
concentration  of  ALT  could  significantly  predict  the 
cases with > 33% hepatocytes involvement from the mild 
hepatosteatosis condition (AUC = 0.616, p = 0.020; Figure 
1). In addition, a cut-off value of 58.5 U/L had a sensitivity 
of 66% and a specificity of 50% to detect patients with 
NAFLD with moderate to severe hepatosteatosis; a cut-off 
value of 77.5 U/L had a sensitivity of 51% and a specificity 
of 65% in these subjects. As illustrated in Figure 2, the AST/
ALT ratio was also a statistically significant tool to predict 
advanced  fibrosis  (AUC  =  0.836,  p  =  0.001).  A  cut-off 
value of 0.88 for the ratio had a sensitivity of 87.5% and a 
specificity of 79.7% to detect patients with severe fibrosis 
or/and cirrhosis. 
Variable Total (n = 147)
Group of patients
P value
ALT < 35 U/L (n = 22) ALT > 35 U/L (n = 125)
Age (y) (Mean ± SD) 41.36 ± 11.18 42.71 ± 11.69 41.11 ± 11.11 0.548
Gender [No. (%)]
Female
Male
20 (13.6%)
127 (86.4%)
6 (27%)
16 (73%)
14 (11.2%)
111 (88.8%)
0.091
BMI (kg/m2) (Mean ± SD) 27.70 ± 3.80 26.77 ± 2.35 27.84 ± 3.96 0.329
Fasting blood sugar (mg/dL) (Mean ± SD) 102.02 ± 36.68 99.25 ± 13.68 102.44 ± 39.06 0.417
Total cholesterol (mg/dL) (Mean ± SD) 202.43 ± 50.33 176.85 ± 36.97 206.66 ± 51.10 0.014
Triglyceride (mg/dL) (Mean ± SD) 208.20 ± 132.15 206.00 ± 139.75 208.58 ± 131.43 0.470
LDL-Cholesterol (mg/dL) (Mean ± SD) 124.28 ± 42.39 122.13 ± 28.95 124.66 ± 44.47 0.833
HDL-Cholesterol (mg/dL) (Mean ± SD) 44.28 ± 19.67 39.00 ± 7.52 45.11 ± 20.86 0.236
PTT (s) (Mean ± SD) 12.49 ± 1.46 13.05 ± 0.61 12.40 ± 1.54 0.122
Platelet count (/L) (Mean ± SD) 343612 ± 479131 502000 ± 836990 325568 ± 425416 0.746
AST (U/L) (Mean ± SD) 54.89 ± 32.41 25.14 ± 14.35 59.97 ± 31.92 <0.001
Alk-P (U/L) (Mean ± SD) 185.04 ± 184.17 134.63 ± 60.84 193.09 ± 195.81 0.200
Table 2. Baseline and clinical characteristics of patients with NAFLD stratified by serum ALT levelHepat Mon. 2011;11(6):452-458
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5. Discussion 
NAFLD which closely resembles alcohol-induced liver 
injury  according  to  histological  features  is  a  clinico-
histopathological  entity  that  occurs  in  patients  with 
little or no history of alcohol consumption. It has a wide 
histological  spectrum  ranging  from  fat  accretion  in 
hepatocytes  without  inflammation  or  fibrosis  (simple 
hepatic  steatosis)  to  hepatic  steatosis  with  necro-
inflammatory elements (steatohepatitis) that may or may 
not have associated fibrosis (17). Presence of fibrosis and 
inflammation is termed “non-alcoholic steatohepatitis” 
(NASH), which may eventually progress to cirrhosis in 
up to 20% of patients (7). ALT is found in the cytosol of 
hepatocytes where it transfers amino groups, while the 
major  site  for  AST  is  mitochondria  (18).  Amino  group 
transfer  from  alanine  to  ketoglutarate  is  catalyzed  by 
ALT. Even though, ALT is mostly specific to liver, it can be 
found in blood during muscle injuries or inflammation 
(19, 20). It has been suggested that elevated liver enzymes 
does not strongly correlate with the level of liver injury, 
fibrosis or inflammation (21); however, it is a diagnostic 
evaluation hint.
The main objective of this study was to evaluate the 
pathologic findings in patients with NAFLD according 
to the ALT level (above vs. below 35 U/L). Our findings 
demonstrated  that  by  considering  the  current  cut-off 
value of 35 U/L, there is no significant difference between 
patients  with  NAFLD  according  to  their  pathologic 
findings except for ballooning of hepatocytes which is a 
minor finding compared to more frequent presentations 
such as fibrosis. This could be partially explained by the 
variability of ALT level in patients in NASH which has 
been confirmed by previous studies (22, 23). In the third 
National  Health  and  Nutrition  Examination  Survey 
(NHANES), the variation in ALT was studied among two 
measurement results in the American people. About 30% 
of patients with firstly elevated ALT had normal values 
on the repeated testing. Likewise, our results concerning 
ALT in NAFLD subjects showed variability according to 
the histopathologic findings (22). In another study, 29% 
of those with NAFLD with normal ALT had elevated ALT on 
repeated testing and 38% of those with elevated ALT had 
normal ALT at the next visit (23). The high inconsistency 
was comparable in patients with simple steatosis and 
NASH. The within patient coefficient of variation for ALT 
in the second cohort was greater than that reported in 
NHANES (33.6 vs. 20.4) (22, 23). 
Finding Total (n = 147)
Group of patients
P value
ALT < 35 U/L (n = 22) ALT > 35 U/L (n = 125)
Hepatosteatosis
Grade I [No. (%)]
Grade II [No. (%)]
Grade III [No. (%)]
Grade (Mean ± SD) 
66 (44.9%)
58 (39.5%)
23 (15.6%)
1.71 ± 0.72
13 (59%)
7 (32%)
2 (9%)
1.50 ± 0.67
53 (42.4%)
51 (40.8%)
21 (16.8%)
1.74 ± 0.73
0.324
0.136
Fibrosis
No fibrosis [No.  (%)]
Grade I [No. (%)]
Grade II [No. (%)]
Grade III [No. (%)]
Cirrhosis [No. (%)]
Grade (Mean ± SD) 
103 (69.7%)
29 (20%)
7 (4.8%)
3 (2.1%)
5 (3.4%)
0.49 ± 0.94
19 (87%)
1 (5%)
1 (5%)
—
1 (5%)
0.32 ± 0.95
84 (67.2%)
28 (22.4%)
6 (4.8%)
3 (2.4%)
4 (3.2%)
0.52 ± 0.94
0.327
0.104
Hepatocyte ballooning
No ballooning [No. (%)]
Grade I [No. (%)]
Grade II [No. (%)]
Grade III [No. (%)]
Grade (Mean ± SD) 
127 (86.8%)
12 (7.6%)
7 (4.9%)
1 (0.7%)
0.20 ± 0.54
22 (100%)
—
—
—
0
105 (84%)
12 (9.6%)
7 (5.6%)
1 (0.8%)
0.23 ± 0.58
0.254
0.045
Lobar inflammation
No change [No. (%)]
Grade I [No. (%)]
Grade II [No. (%)]
Grade (Mean ± SD) 
102 (69.7%)
38 (26.1%)
7(4.2%)
0.35 ± 0.57
17 (77.3%)
5 (22.7%)
—
0.23 ± 0.43
85 (68%)
33 (26.4%)
7 (5.6%)
0.38 ± 0.59
0.458
0.328
Portal inflammation
No change [No. (%)]
Grade I [No. (%)]
Grade II [No. (%)]
Grade III [No. (%)]
Grade (Mean ± SD) 
113 (77.1%)
26 (17.4%)
6 (4.2%)
2 (1.3%)
0.30 ± 0.61
19 (86.4%)
2 (9.1%)
—
1 (4.5%)
0.23 ± 0.68
94 (75.2%)
24 (19.2%)
6 (4.8%)
1 (0.8%)
0.31 ± 0.60
0.224
0.282
 
Table 3. Histopathologic characteristics of patients with NAFLD stratified by serum ALT levelHepat Mon. 2011;11(6):452-458
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Previous studies have demonstrated that occurrence of 
significant fibrosis in NASH might be seen in patients with 
NAFLD who had a normal ALT value (14, 24). One option is 
that those were false reports due to the implementation 
of unsuitable ALT cut-off values. In a retrospective study 
of 51 patients with normal ALT levels, bridging fibrosis 
was seen in 12 and cirrhosis was found in six patients 
(14). However, the cut-off value they used was 52 U⁄L for 
women and 75 U⁄L for men. On the other hand, the mean 
ALT level in patients with normal ALT was 40 U⁄L, which 
would be considered abnormal according to the current 
standard.  Fracanzani  et  al.  studied  63  patients  with 
normal  ALT  and  reported  that  normal  ALT  correlated 
with  less  severe  steatosis  and  necro-inflammation; 
however, they could not find any correlations between 
the severity of fibrosis and ALT levels. They considered 
ALT values < 40 U/L as normal (25). Another retrospective 
study performed by Kunde et al. on 233 obese women 
who underwent liver biopsies during bariatric surgery 
showed that patients with ALT < 19 U⁄L had less severe 
histopathologic findings. However, 23% and 5% of patients 
still had NASH and advanced fibrosis, respectively (26). 
Wong et al. confirmed that ALT levels do not correlate 
well  with  metabolic  and  histological  parameters  in 
patients  with  NAFLD.  Their  results  demonstrated  that 
NASH and significant fibrosis can be found even among 
those with ALT below half of the upper normal limit (24). 
Our results were also in concordance with these finding 
as we could not find any correlation between ALT levels 
and histopathologic or metabolic abnormalities in these 
patients. More recently, another multi-center study was 
conducted on 733 patients with NAFLD who had biopsy 
specimens;  it  showed  that  the  presence  of  advanced 
fibrosis was not correlated with ALT levels (12). It seem 
that using ALT level as a marker for severe NAFLD would 
result in considering high risk patients as mild cases as 
with  normal  ALT,  there  is  still  risk  of  progressive  and 
severe hepatic disease.
Previous  large  population-based  studies  have  shown 
that abnormal ALT levels (ALT > 43 U/L) are present in 2.8% 
of adult population which increases to 6.6% in class II or 
III obesity (27). Using the same ALT cut-off value (43 U/L), 
another study performed by Kunde et al. (26) showed 
elevated ALT levels in 8.6% of their study population which 
consisted of women with class II or III obesity. In our study, 
we used a cut-off value of 30 U/L for ALT; according to this 
level, 125 (85%) of 147 patients had abnormal ALT levels. A 
comparison of our study to the mentioned studies is not 
possible because of the different target populations. Our 
study  had  several  limitations  considering  the  design. 
The  most  important  of  all  was  the  small  sample  size 
which was due to the unacceptable nature of liver biopsy 
among  patients.  Secondly,  the  cross-sectional  design 
of the study would be a limitation. Cohort studies with 
multiple  biopsies  during  the  course  of  disease  while 
measuring ALT level in a periodic schedule would help 
to more precisely interpret the findings in correlation 
to  ALT  level.  However,  the  invasiveness  of  liver  biopsy 
procedure and ethical issues are the major limiting factor 
of  such  studies.  We  recommend  larger  multi-center 
cohorts  with  large  sample  sizes  being  followed  with 
a  unique  protocol  while  their  clinical,  laboratory  and 
histopathological data is being recorded. Such studies 
might  be  able  to  answer  our  questions  considering 
the important issues about NAFLD course and severity. 
Altogether, our results underline the little contribution 
 Area under curve [AUC] = 0.616, p = 0.020
Figure 1. ROC curve analysis of serum ALT level to predict more than 33% 
hepatocytes involvement in hepatosteatosis of patients with NAFLD without 
advanced fibrosis
Area under curve (AUC)=0.836, P=0.001
Figure 2. ROC curve analysis of AST/ALT ratio to predict advanced fibrosis in 
NAFLD patients Hepat Mon. 2011;11(6):452-458
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of ALT as an independent factor for detecting the severity 
of NAFLD. Therefore, using ALT levels as an indicator of 
severity might result in false reassurance of patients and 
physicians.
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